期刊文献+

重组人胸腺肽α1在大肠杆菌中的表达纯化与鉴定

Expression,Purification and Identification of Recombinant Human Thymosin-alpha 1 in Escherichia coli
下载PDF
导出
摘要 采用大肠杆菌作为宿主表达重组人胸腺肽α1(rhTα1)融合蛋白,纯化获得rhTα1并对其鉴定.于300L发酵罐进行中试发酵表达rhTα1融合蛋白;经异丙基-β-D-硫代吡喃半乳糖苷(IPTG)诱导,离心发酵液收集菌体,菌体经破碎、离心、亲和层析捕获,获得融合蛋白;每升发酵液可获得约170 mg硫氧环蛋白-胸腺肽α1融合蛋白.融合蛋白经肠激酶酶切后,再经亲和层析、反相层析、体积排阻层析等纯化步骤,获得高纯度rhTα1;通过本纯化工艺获得的rhTα1原液经十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和高效液相色谱-排阻法(HPLC-SEC)的检测纯度均大于99%;采用玫瑰花环形成率测定rhTα1活性与市售化学合成标准品一致;质谱分析分子质量为3 066.59u,与去乙酰化的rhTα1理论分子质量(3 066u)一致;N端测序结果与理论值一致.综上结果,说明本工艺可实现工业化规模生产. In the present study,expression,purification and identification of recombinant human thymosin-alpha 1(rhTα1)in Escherichia coli were reported.Firstly,bacteria expressing the rhTα1fusion protein were utilized in the 300 Lfermentator,and protein was induced by IPTG.Then,bacteria were harvested by centrifugation,and cell lysate was obtained using high pressure crushes.The crude protein was purified using the affinity chromatograghy,and the yield of the fusion protein was up to 170 mg per 1Lculture.Furthermore,the crude protein was processed by enterokinase(EK)proteolysis,affinity chromatography,reversed phase chromatography and exclusion chromatography to obtain the high purity of rhTα1.SDS-PAGE and HPLC-RPC analysis indicated that rhTα1could reach the purity of more than 99%.Additionally,rosette formation assay demonstrated that the activity of rhTα1was quite similar to that of the commercial standard product.Molecular weight of rhTα1by MALDI-TOF MS was 3 066.59 u,which agreed with the theoretic result(3 066u),and the analysis of N-terminal of rhTα1showed an accordance with the theoretic data,which all implied a potential for the industrialization of rhTα1.
出处 《厦门大学学报(自然科学版)》 CAS CSCD 北大核心 2016年第2期192-197,共6页 Journal of Xiamen University:Natural Science
基金 国家高技术研究发展计划(863)项目(2007AA021604)
关键词 重组人胸腺肽α1(rhTα1) 表达 纯化 recombinant human thymosin-alpha 1(rhTα1) expression purification
  • 相关文献

参考文献13

  • 1SUGAHARA S,ICHIDA T,YAMAGIWA S,et al.Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B[J].Hepatol Research,2002,24(4):346-354.
  • 2SARUC M,YUCEYAR H,KUCUK M N,et al.Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey[J].Hepatogastroenterology,2002,49(45):798-802.
  • 3SARUC M,OZDEN N,TURKEL N,et al.Long-term outcomes of thymosin-alpha 1 and interferon-alpha 2b combination therapy in patients with hepatitis Be antigen(HBeAg)negative chronic hepatitis B[J].Journal of Pharmaceutical Sciences,2003,92(7):1386-1395.
  • 4GARACI E.Sequential chemo immunotherapy for advanced non-small cell lung cancer using cisplatin,etoposide,thymosin alpha l and interferon-alpha 2a [J].Europen Journal of Cancer 31A,1995,31:2403-2405.
  • 5SCHULOF S R. An evaluation of two different schedules of synthetic thymosinα1 administration in patients with lung cancer[J]. Preliminary Results,1960,6:601-613.
  • 6GOLDSTEIN A L,LOW T L K,MC DOO M,et al.Thymosin-alpha 1:isolation and sequence analysis of an immunologically active thymic polypeptide[J].Proceeding of the National Academy of Science of the United States of America,1977,74:725-729.
  • 7王孟军.胸腺素类免疫调节剂研发现状分析[J].中国新药杂志,2014,23(20):2344-2348. 被引量:7
  • 8刘中禄,陶翠兰,莘旭妮,李树民.重组胸腺素α1 pMAL-C2x-Tα1/TB1工程菌的构建与表达[J].中国比较医学杂志,2012,22(7):13-16. 被引量:5
  • 9熊燕燕,汤斌.胸腺肽α1在毕赤酵母中的表达及纯化[J].安徽工程大学学报,2013,28(2):4-6. 被引量:3
  • 10国家食品药品监督管理局.胸腺肽溶液质量标准:WS1-XG 042-2000-2003 [J].中国药品标准,2003,4(6):17-18.

二级参考文献51

  • 1金明飞,徐伟东,黄静,金丽,王嘉,叶海峰,吴自荣.基因串联原核高效表达胸腺肽α1[J].中国生物工程杂志,2007,27(1):11-15. 被引量:10
  • 2秦伟涛,陈劲春,李冬冬.一种简便快速工艺制备重组人胸腺肽α_1[J].北京化工大学学报(自然科学版),2007,34(3):296-299. 被引量:3
  • 3陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:32-33.
  • 4张树军,杨磊,黄瑾.巴斯德毕赤酵母表达系统的研究进展[J].农垦医学,2007,29(3):231-233. 被引量:5
  • 5Knutsen AP, Freeman JJ, Mueller KR, et al. Thymosin-alphal stimulates maturation of CD34 + stem ceils into CD3 + 4 + cells in anin vitrothymic epithelia organ coculture model [ J ]. Int J Immunopharmacol, 1999,21 ( 1 ) : 15 - 26.
  • 6Ancel CD, Phipps J, Young L. Thymosin alpha 1 [ M]. Am J Heahh-Syst-Pharm, 2001,58:879 - 885.
  • 7Salvati F, Rasi G, Portalone L, et al. Combined treatment with thymosin-alphal and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial [ J ]. Antieancer-Res, 1996,16 (2) : 1001 - 1004.
  • 8Ramaehandran R, Katzenstein DA, Winters MA, et al. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodefieiency virus type 1 infection [ J ]. J Infect Dis, 1996,173(4) :1005 - 1008.
  • 9Arno Sungarian, Deus Cielo,Prakash Sampath,et al. Potential Role of Thymosin-al adjuvant therapy for glioblastoma Tal [J]. Journal of Oncology, 2009 :11.
  • 10Weina Li,Liqiang Song, Shouzhen Wu,et al. Expression, purification and Characterization of A Novel Soluble Human Thymosin Alpha1 Concatemer Exhibited A Stronger Stimulation on Mice Lymphocytes Proliferation and Higher Anti- tumor Activity[J]. International Journal of Biological Sciences, 2011,7 (5) : 618-628.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部